Quick Answer
Xenetic Biosciences, Inc. reported Total Revenue of $2.98 million for fiscal year 2025.
Xenetic Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $2.98M +19.0% |
$2.50M -1.6% |
$2.54M +48.8% |
$1.71M +47.1% |
$1.16M +165.6% |
$436.9K +2460.3% |
| Net Income | -$2.68M +32.3% |
-$3.96M +4.2% |
-$4.13M +36.9% |
-$6.55M -16.1% |
-$5.65M +48.2% |
-$10.89M +14.7% |
| Diluted EPS | -$1.58 +38.5% |
-$2.57 +5.2% |
-$2.71 +41.2% |
-$4.61 | — | — |
| Total Assets | $8.36M +21.2% |
$6.90M -34.9% |
$10.61M -28.0% |
$14.72M -25.7% |
$19.82M +50.3% |
$13.18M -38.8% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $7.40M +23.1% |
$6.01M -38.7% |
$9.80M -28.2% |
$13.65M -25.8% |
$18.39M +50.6% |
$12.22M -29.0% |
| R&D Expense | $3.07M -6.8% |
$3.29M -5.9% |
$3.49M -26.7% |
$4.77M +50.8% |
$3.16M +82.7% |
$1.73M -64.6% |
| Operating Income | -$2.83M +32.6% |
-$4.20M +6.9% |
-$4.52M +32.8% |
-$6.72M -16.9% |
-$5.75M +58.8% |
-$13.94M -8.2% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 2.29M +48.6% |
1.54M +0.1% |
1.54M +1.6% |
1.52M -88.7% |
13.44M +53.7% |
8.75M +44.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.03M | +67.2% | +74.1% |
| Net Income | September 30, 2025 | -$509.9K | -16.8% | +26.0% |
| Diluted EPS | September 30, 2025 | -$0.33 | -17.9% | +26.7% |
| Total Assets | September 30, 2025 | $5.07M | -37.0% | -5.3% |
| Long-Term Debt | August 31, 2016 | $212.8K | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $3.96M | -43.8% | -11.1% |
| R&D Expense | September 30, 2025 | $756.5K | +105.6% | +15.2% |
| Operating Income | September 30, 2025 | -$544.7K | -9.1% | +24.8% |
| Gross Profit | March 31, 2015 | $0.00 | — | — |
| Shares Outstanding | September 30, 2025 | 1.54M | +0.0% | +0.0% |
- Xenetic Biosciences, Inc. reported Total Revenue of $2.98 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +19.0% in Total Revenue compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Net Income of -$2.68 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +32.3% in Net Income compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +38.5% in Diluted EPS compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Total Assets of $8.36 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +21.2% in Total Assets compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Long-Term Debt of $212.8 thousand for fiscal year 2013.
- Xenetic Biosciences, Inc. showed an increase of +0.0% in Long-Term Debt compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Stockholders Equity of $7.40 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +23.1% in Stockholders Equity compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported R&D Expense of $3.07 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed a decrease of -6.8% in R&D Expense compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Operating Income of -$2.83 million for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +32.6% in Operating Income compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Gross Profit of $0.00 for fiscal year 2014.
- Xenetic Biosciences, Inc. showed a decrease of -100.0% in Gross Profit compared to the prior fiscal year.
- Xenetic Biosciences, Inc. reported Shares Outstanding of 2.29 million shares for fiscal year 2025.
- Xenetic Biosciences, Inc. showed an increase of +48.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: